Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 2Phase 1/2 1

Status

Recruiting 2

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Breast Neoplasms 3499Neoplasms 2740Prostatic Neoplasms 1583Colorectal Neoplasms 1248Lung Neoplasms 1188Motor Activity 766Head and Neck Neoplasms 621Pancreatic Neoplasms 601Colonic Neoplasms 586Uterine Cervical Neoplasms 567Carcinoma, Non-Small-Cell Lung 560Carcinoma, Hepatocellular 559Rectal Neoplasms 516Stomach Neoplasms 493Brain Neoplasms 438Anxiety Disorders 401Ovarian Neoplasms 399Pain 376Esophageal Neoplasms 347Polycystic Ovary Syndrome 341Neoplasm Metastasis 340Fatigue 324Urinary Bladder Neoplasms 314Precursor Cell Lymphoblastic Leukemia-Lymphoma 303Melanoma 298Depression 286Multiple Myeloma 283Endometrial Neoplasms 263Lymphoma 258Hematologic Neoplasms 251

Interventions

Radiotherapy 2Immune Checkpoint Inhibitors 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase NA × OTHER × Advanced NSCLC × Clear all
NCT06752044 2024-12-30

Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment

The First Affiliated Hospital of Nanchang University

Phase NA Recruiting
10 enrolled
Thoracic

Advanced NSCLC

NCT06752057 2024-12-30

Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment

The First Affiliated Hospital of Nanchang University

Phase NA Recruiting
10 enrolled
Thoracic

Advanced NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡